tbuckley/cabot-search huggingface dataset:
The Utilization of Radioactive Iodinated Hippuran for Determination of Renal Clearance Rates
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Authors: B Euston, B Scotrish
Journal: BMJ (1943)

CheiropompholyxQ.-Is it accepted that cheiropompholyx is caused by a fungous infection in distant parts of the body?A.-The term " cheiropompholyx " is more significant if reserved for an eczematous eruption of itching, deep, tense vesicles which erupt, periodically or episodically, without obvious cause, although nervous factors and local irritation are provocative, as in other types
Continuing Medical Education
Authors: Arthur M. Osteen
Journal: JAMA (1987)

<h3>ACCREDITATION ACTIVITIES</h3> The number of sponsors of continuing medical education (CME) accredited by state medical societies and the general classification of these sponsors are given in Table 1. The total increased only slightly from last year, 1871 compared with 1861. Since this number has not increased significantly over the past few years, it appears that most intrastate organizations desiring CME accreditation have already been accommodated. Seventy-two percent of state-accredited sponsors of CME are hospitals. Not included in this list, however, are hospitals affiliated with medical schools for their CME programs, which come under the accreditation of the medical school. The number of these hospitals varies for each medical school, and accurate information is unavailable. A few medical schools report over 50 CME-affiliated hospitals, while most appear to have about ten. The number of sponsors of CME accredited directly by the Accreditation Council for Continuing Medical Education (ACCME) has also increased
Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
Authors: M. Friedlander, K. Moore, N. Colombo, G. Scambia, B.-G. Kim, A. Oaknin, A. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, S. Banerjee, A.M. Oza, A. González-Martín, C. Aghajanian, W. Bradley, E.S. Lowe, R. Bloomfield, P. Disilvestro
Journal: Annals of Oncology (2018)
OBSTETRICAL SOCIETY OF PHILADELPHIA.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"PROTEIN AND PELLAGRA"
Authors: Joseph Goldberger
Journal: JAMA (1923)

<h3>To the Editor:</h3> —In his reply, last week, to my comment on his article, Professor Hindhede first considers a point which I referred to as of no vital importance, and, secondly, states that "Dr. Goldberger has changed his mind," without really making clear about what "Dr. Goldberger has changed his mind," assuming (what is not a fact) that he changed his mind, and without showing what relation, if any, this has to the major issues raised by him on which I commented. In my comments, if I may be permitted to recall, I addressed myself to three or four points, of which only two were regarded as of real importance. These were: 1. The charge that Goldberger and associates were reprehensible advocates of the view that pellagra is caused by lack of animal protein. 2. The argument in support of Hindhede's view that "the question of pellagra is not a
Storm
Authors: Noel Crook
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute systemic reactions to carbonless copy paper associated with histamine release
Authors: F. P. LaMarte
Journal: JAMA (1988)

We report two cases of recurrent episodes of hoarseness, cough, flushing, pruritus, and rash occurring within 30 minutes of topical exposure to carbonless copy paper. Provocative challenges revealed that alkylphenol novolac resin was the ingredient responsible. Video endoscopy of the larynx was performed and plasma histamine levels were obtained prior to and 30 minutes after cutaneous challenge of a patient with alkylphenol novolac resin. We documented marked laryngeal edema and a sixfold increase in plasma histamine levels after challenge. We conclude that topical exposure to carbonless copy paper may cause mast cell/basophil-mediated acute systemic and potentially life-threatening reactions in susceptible patients. (<i>JAMA</i>1988;260:242-243)
NOTES ON OPHTHALMIC DISEASES
Authors: J. V. Solomon
Journal: BMJ (1854)

Tm *!Gt1AL COMMNICATONS.81 orcsu in the othr.So invsziably did this obtain, that, luudio on h after an inteval of vaying extent, during which no csNa ofue in either place, that a person had been attacked at Leith, I made preparations for the reception of patients in Edinburgh; and I do not remember having been once disappointed in my anti- cipations Nofte on the Progrs of the Epidemic, etc., during the montb of October, Koember, and December 1853.Oct. 3rd.Two or three sporadic cases occurred about this date in Edinburgh and Leith.Oct. 27th.A simultaneous outburst in Edinburgh and Dundee, in different quarters of their respective towns.Oct. 30th.Several isolated and grouped cases occurred in Edinburgh.Communication was distinctly traceable between several foci.Nov. lst.About this date epidemic spread in London, Dublin, Dundee, and various other parts of Britain.Nov. 12th.Several sporadic cases occurred in distant parts of the town.From Nov. 13th to 21st there were no cases in hospital or in town.Nov. 22nd.A fatal case occurred in Leith, and another in Edinburgh.Nov. 26th.One of the dogs on which I had been ex- perimenting died of cholera: and on the 27th another: the remaining animals recovered slowly but completely.Nov. 29th.Two or three cases in Edinburgh.At Dundee the disease raged with great virulence: the mortality being about 45 per cent.Up to the 10th there had been one hundred and sixty cases, of which seventy-two were fatal.*At Arbroath, though much more limited in its diffusion, the disease was still more fatal: the deaths included a medical student and a cholera~z-rse.Dec. 6th.Several new foci formed: the cases equally fatal as at the first outburst of the disease.Dec. 14th.During the previous week, several fatal cases had occurred in distant parts of the new town, among the middle and upper classes, who were attacked in a comparatively large ratio throughout the epidemic.Dec. 20th.Five cases were reported in town and one in Edinburgh.During the previous week there had been a few sporadic cases.Dec. 21st.Broke out in Glasgow, and also made its appearance in various of the smaller towns and villages of England and Scotland.[To be continued.]
Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis
Journal: Annals of Internal Medicine (2001)

Summaries for Patients2 October 2001Delayed-Onset Heparin-Induced Thrombocytopenia and ThrombosisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-7-200110020-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Blood thinners, such as heparin, are often needed to treat patients who have developed (or are at risk for) blood clots in their veins or arteries. It has been known for many years that a small proportion of these patients has an adverse reaction to heparin administration characterized by a decrease in the number of platelets (particles that are necessary for blood clot formation) circulating in the blood. This abnormality is known as heparin-induced thrombocytopenia. The reaction is caused by development of antibodies (proteins made by the immune ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis.” It is in the 2 October 2001 issue of Annals of Internal Medicine (volume 135, pages 502-506). The authors are TE Warkentin and JG Kelton.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDelayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis Theodore E. Warkentin and John G. Kelton Metrics 2 October 2001Volume 135, Issue 7Page: I-45KeywordsAntibodiesArteriesDrugsHematologic testsHeparinHeparin-induced thrombocytopeniaImmune system proteinsPlateletsThrombosisVeins ePublished: 2 October 2001 Issue Published: 2 October 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Reply
Authors: Margaret L. Kripke, Tibor Borsos
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Reply Get access Margaret L. Kripke, Ph.D., Margaret L. Kripke, Ph.D. College of Medicine University of Utah, Salt Lake City, Utah 84112 Search for other works by this author on: Oxford Academic PubMed Google Scholar Tibor Borsos, Sc.D. Tibor Borsos, Sc.D. Biology Branch National Cancer Institute, Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 1, January 1975, Pages 281–282, https://doi.org/10.1093/jnci/54.1.281 Published: 01 January 1975
Osteitis Pubis
Authors: M. Abrams, I. Sedlezky, David B. Stearns
Journal: New England Journal of Medicine (1949)

THE number of reported cases of osteitis pubis following suprapubic or retropubic prostatectomy1 2 3 4 5 6 7 8 9 10 11 suggests that it is a rare complication. Since this is not in accord with our own experience we herewith present 5 cases with observations relating to diagnosis and treatment. Two of them followed retropubic prostatectomy, and 2 followed suprapubic prostatectomy; the fifth case followed an abdominoperineal resection for carcinoma of the rectum.Case ReportsCase 1. J. W., a 61-year-old man, was admitted to the hospital with the chief complaint of frequency of urination during the day and night and hesitancy and diminution in the force of . . .
No transfats
Authors: Brent A. Neuschwander-Tetri
Journal: Hepatology (2011)

The recent report of nonalcoholic steatohepatitis–like features and liver fibrosis in mice fed a diet high in saturated fats and high-fructose corn syrup by Kohli et al.1 is another important addition to our understanding of the pathogenesis of nonalcoholic steatohepatitis. However, readers should be aware that there is an error in this article's title, which indicates that the mice were fed a diet containing transfats. The fat fed to the mice in these experiments came from fully hydrogenated coconut oil. According to materials available from the manufacturer, Research Diets, the naturally low monounsaturated and polyunsaturated fat content of coconut oil (8.2%) is reduced to 0.8% through hydrogenation, and the rest (99.2%) is saturated fat. The unsaturated fat (0.8%) is monounsaturated fatty acid oleic acid, so the diet does not contain transfats. This error in describing the composition of the diet highlights the importance of including as much detail as possible in the Materials and Methods section with respect to the sources of fat, carbohydrates, and protein in animal diets used to induce features of nonalcoholic steatohepatitis. Brent A. Neuschwander-Tetri M.D.*, * Division of Gastroenterology and Hepatology, St. Louis University, St. Louis, MO.
Ultramorphological Sperm Characteristics in the Risk Assessment of Health Effects after Radiation Exposure among Salvage Workers in Chernobyl
Authors: Alf Fischbein, Natalia Zabludovsky, Fina Eltes, Valentin Grischenko, Benjamin Bartoov
Journal: Environmental Health Perspectives (1997)

We present a pilot study of individuals (liquidators) who were engaged in clean-up operations after the disaster at the nuclear power plant at Chernobyl in Ukraine.In the 10 years since the disaster, adverse health effects among exposed individuals have not been clearly defined.There is widespread fear of damage to the reproductive system, with implications for fertility problems and adverse effects on offspring.Bearing this in mind, methods to evaluate the potential for production of fertile semen have been applied using quantitative ultramorphological (QUM) analysis.QUM analysis examines the organization and integrity of sperm organelles by electron microscopy, using both transmission electron microscopy and scanning electron microscopy.Significant differences were observed between clean-up workers and controls of similar age regarding certain ultramorphological parameters of the sperm head.The results of this pilot study suggest that QUM analysis of human sperm is a feasible approach for evaluating the fertility potential of individuals who were exposed to ionizing radiation from the Chernobyl nuclear power plant accident.
Officials of the Association
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Windblown Pesticide Hazard
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: Really safe and effective? #
Authors: Bruce R. Bacon
Journal: Hepatology (2009)

As the investigators of the DIRECT trial, we thank Dr. Lo for his support of our study using interferon alfacon-1 [consensus interferon (CIFN)]/ribavirin (RBV) for the retreatment of pegylated interferon (PEG-interferon)/RBV nonresponders. It should be noted that there were no relapsers in our study, 80% of the patients were null responders to prior PEG-interferon/RBV, and 62% of the patients had advanced fibrosis. Accordingly, this was a very difficult to treat group of PEG-interferon/RBV nonresponders. In the DIRECT trial, the sustained virological response (SVR) rate with CIFN/RBV was 10.7% for the 15-μg CIFN group, whereas SVR rates of 2% to 6% were found when PEG-interferon/RBV nonresponders were retreated with PEG-interferon/RBV.1, 2 The nonresponder studies referenced by Dr. Lo from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial, a study by Dr. Sherman, and the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC) trial have reported higher SVR rates but included prior interferon or interferon/RBV nonresponders and relapsers. Furthermore, studies have been reported in which the prior response to PEG-interferon/RBV was unknown.3 Unfortunately, Dr. Lo seems to be grouping all of these nonresponders together, whereas in the DIRECT trial, we treated only PEG-interferon/RBV nonresponders. We agree with Dr. Lo that adherence to therapy in this population is difficult and that some patients cannot tolerate adverse events. Nonetheless, we stand by our conclusion that the combination of CIFN and RBV for PEG-interferon/RBV nonresponders is safe and efficacious. Furthermore, it has been shown that if HCV RNA levels are undetected at week 12 (complete early virological response), then ultimate SVR is achieved in approximately 75% of patients. With this information in mind, the standard 12-week stopping rule can be used, and this will reduce the exposure to antiviral therapy in patients for whom no response would occur. Bruce R. Bacon*, * Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO.
Abstract 18950: Changes in Vasodilator Reactivity and Vasoconstrictor Tone in Metabolically Healthy Obesity and the Metabolic Syndrome
Authors: Micaela Iantorno, Francesca Schinzari, Nadia Mores, Manfredi Tesauro, Nicola Di Daniele, Umberto Campia, Carmine Cardillo
Journal: Circulation (2015)

Background: Patients with obesity-related metabolic syndrome (MetS) have endothelial dysfunction due to decrease nitric oxide (NO) availability and increased endothelin (ET)-1-mediated vasoconstrictor tone. Given the prognostic significance of endothelial dysfunction, these abnormalities may be involved in the increased risk of cardiovascular mortality of these patients. Whether patients with metabolically healthy obesity (MHO), in whom those metabolic abnormalities that define the MetS are not present, have similar impairment of endothelial function is unknown. Methods: Forearm blood flow (FBF) responses were measured by strain-gauge plethysmography during intra-arterial infusion of graded-doses of acetylcholine (ACh; an endothelial-dependent vasodilator) and sodium nitroprusside (SNP; an endothelium-independent vasodilator), and/or during selective antagonism of ETA receptors by BQ-123 (10 nmol/min for 60 minutes) in lean subjects (n=56) and in obese patients (n=119), with either MHO (n=34) or the MetS (n=85). Results: ACh and SNP caused vasodilation in both obese and lean participants (all P&lt;0.001 vs. baseline). The response, however, to both agents was significantly lower in the obese than in the control group (both P&lt;0.001). Among the obese participants, the reactivity to ACh was higher in MHO than in the MetS (P&lt;0.001), whereas the responsiveness to SNP was equally impaired in both groups (P=0.45); this suggests higher degree of endothelial dysfunction in the MetS, but similar impairment of smooth muscle reactivity in MHO and the MetS. As expected, BQ-123 increased FBF in obese (P&lt;0001 vs. baseline), but not in lean participants, hence the FBF response to ETA receptor blockade was higher in both obese groups than in controls (both P&lt;0.001). In keeping with the ACh results, the FBF response to BQ-123 was significantly higher in patients with the MetS than in those with MHO (P=0.007). Conclusions: Patients with MHO have abnormal vascular reactivity, albeit their endothelial dysfunction is less pronounced than in patients with the MetS. These findings indicate that obesity per se is associated with some degree of vascular damage independently of those metabolic abnormalities underlying the MetS.